Yahoo Finance·2026-01-20 22:30Group 1 - Rapt Therapeutics' shares increased over 60% following the announcement of its acquisition by GSK for $2.2 billion [1] - Investors in Rapt will receive $58.00 per share, representing a premium of over 65% compared to the closing price on January 16, prior to the acquisition announcement [3] - The acquisition grants GSK global rights to ozureprubart, an experimental antibody treatment for food allergies, which is currently in phase 2 clinical trials [4] Group 2 - There is a significant unmet need for treatments targeting food allergies, with over 17 million people affected in the U.S., including 1.3 million with severe reactions [6] - Rapt's investigational treatment targets a protein responsible for approximately 94% of severe food allergies, indicating its potential impact on public health [6] - The deal is expected to close in the first quarter, pending regulatory approval [5]